Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Lexicon Pharmaceuticals, Inc.    LXRX

 SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Financials ($)
Sales 2016 77,1 M
EBIT 2016 -154 M
Net income 2016 -164 M
Debt 2016 38,0 M
Yield 2016 -
Sales 2017 86,2 M
EBIT 2017 -188 M
Net income 2017 -191 M
Debt 2017 81,0 M
Yield 2017 -
P/E ratio 2016 -
P/E ratio 2017
EV / Sales2016 21,7x
EV / Sales2017 19,9x
Capitalization 1 635 M
More Financials
Company
Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company, focuses on the development of breakthrough treatments for human disease.It has multiple programs in clinical development for diabetes, irritable bowel syndrome, carcinoid syndrome and other indications.Lexicon Pharmaceuticals was founded... 
More about the company
Surperformance© ratings of Lexicon Pharmaceuticals, I
Trading Rating : Investor Rating :
More Ratings
Latest news on LEXICON PHARMACEUTICALS, I
01/19 LEXICON PHARMACEUTICALS : Begins Phase 1 Clinical Trial Of Locally-acting SGLT1 ..
01/12 LEXICON PHARMACEUTICALS : To Present At The 35th Annual J.P. Morgan Healthcare C..
2016 LEXICON PHARMACEUTICALS : Reports Positive Top-line Results In Second Pivotal Ph..
2016 LEXICON PHARMACEUTICALS, INC. : Blog Coverage Lexicon Pharma's Tandem2 Phase 3 C..
2016 BIOTECH MOVERS AND SHAKERS : Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) and Neu..
2016 LEXICON PHARMACEUTICALS : To Present At The Stifel 2016 Healthcare Conference An..
2016 LEXICON PHARMACEUTICALS : Acquires Exclusive Rights To Development Candidate For..
2016 LEXICON PHARMACEUTICALS : to Report Third Quarter 2016 Financial Results on Nove..
2016 LEXICON PHARMACEUTICALS : Announces Publication Of TELESTAR Study Results For Te..
2016 LEXICON PHARMACEUTICALS : buys Bristol neuro drug
More news
Sector news : Bio Therapeutic Drugs
08:06aDJSANOFI : Lonza to Invest CHF290 Million in New Plant in Switzerland
02/22 Genmab and J&J's cancer drug set for blockbuster sales this year
02/21 Icahn buys Bristol-Myers shares, adding to activist pressure
02/21DJBristol-Myers Expands Board, Boosts Buybacks Amid Activist Pressure
02/16 How Sanofi lost out to J&J in $30 billion battle for Actelion
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
2015 SEEKING ALPHA'S BIOTECH WEEKLY : A Gilead Victory, Celladon Crumbles, And More
2015 Lexicon Undervalued As It Approaches A Major Event
2015 Lexicon Pharmaceuticals' (LXRX) CEO Lonnel Coats on Q1 2015 Results - Earning..
2015 Lexicon Pharmaceuticals EPS in-line, beats on revenue
2015 Lexicon Pharmaceuticals - A Diamond In The Rough?
Advertisement
Chart LEXICON PHARMACEUTICALS, I
Duration : Period :
Lexicon Pharmaceuticals, I Technical Analysis Chart | LXRX | US5288721047 | 4-Traders
Full-screen chart
Income Statement Evolution
More Financials
Consensus 
Mean consensus OUTPERFORM
Number of Analysts 8
Average target price 24,7 $
Spread / Average Target 57%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Lonnel Coats President, Chief Executive Officer & Director
Raymond Debbane Chairman
Jeffrey L. Wade CFO, EVP-Corporate & Administrative Affairs
Pablo Lapuerta Chief Medical Officer & EVP-Clinical Development
Frank P. Palantoni Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
LEXICON PHARMACEUTICAL..12.10%1 635
AMGEN, INC.19.39%128 555
GILEAD SCIENCES, INC.-2.33%92 143
CELGENE CORPORATION2.14%91 979
REGENERON PHARMACEUTIC..-1.66%38 296
ACTELION LTD22.36%28 792
More Results